XML 148 R133.htm IDEA: XBRL DOCUMENT
v3.22.0.1

SEGMENT INFORMATION - Revenues by Product Category (Details) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2021 USD ($) product | Dec. 31, 2020 USD ($) product | Dec. 31, 2019 USD ($) product
Revenue from External Customer [Line Items] |  |  |
Number of products represented of total revenue | product | 10 | 10 | 10
Revenues | $ 8,434 | $ 8,027 | $ 8,601
Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 3,763 | 3,680 | 4,079
Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,903 | 1,566 | 1,717
OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,532 | 1,430 | 1,447
Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,144 | 1,248 | 1,246
Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 92 | 103 | 112
Bausch + Lomb |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 3,765 | 3,415 | 3,778
Bausch + Lomb | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 514 | 506 | 623
Bausch + Lomb | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,596 | 1,313 | 1,524
Bausch + Lomb | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,388 | 1,311 | 1,322
Bausch + Lomb | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 240 | 254 | 260
Bausch + Lomb | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 27 | 31 | 49
Salix |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 2,074 | 1,904 | 2,022
Salix | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 2,066 | 1,899 | 2,022
Salix | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Salix | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 8 | 5 | 0
International Rx |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 1,166 | 1,181 | 1,154
International Rx | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 259 | 255 | 268
International Rx | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
International Rx | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 136 | 112 | 119
International Rx | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 737 | 775 | 730
International Rx | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 34 | 39 | 37
Ortho Dermatologics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 564 | 548 | 560
Ortho Dermatologics | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 241 | 275 | 353
Ortho Dermatologics | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 307 | 253 | 193
Ortho Dermatologics | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Ortho Dermatologics | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Ortho Dermatologics | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 16 | 20 | 14
Diversified Products |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 865 | 979 | 1,087
Diversified Products | Pharmaceuticals |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 683 | 745 | 813
Diversified Products | Devices |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 0 | 0 | 0
Diversified Products | OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 8 | 7 | 6
Diversified Products | Branded and Other Generics |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | 167 | 219 | 256
Diversified Products | Other revenues |  |  |
Revenue from External Customer [Line Items] |  |  |
Revenues | $ 7 | $ 8 | $ 12
Revenues | Product Concentration Risk | Customer, Top Ten Products |  |  |
Revenue from External Customer [Line Items] |  |  |
Concentration risk, percentage | 43.00% | 41.00% | 39.00%

X
- Definition Concentration Risk, Number Of Products + References No definition available. + Details
Name: | bhc_ConcentrationRiskNumberOfProducts
Namespace Prefix: | bhc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |